[一、表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）的标准治疗是什么？EGFR-TKIs是否改善了非小细胞肺癌的治疗？] - Suppr | 超能文献

[I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].

作者信息

Urata Yoshiko, Satouchi Miyako

出版信息

Gan To Kagaku Ryoho. 2015 Aug;42(8):931-4.

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

[I. What is the Standard Treatment of EGFR-TKIs? Did EGFR-TKIs Improve Treatment for Non-Small Cell Lung Cancer?].

Gan To Kagaku Ryoho. 2015 Aug;42(8):931-4.

2

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.

Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12.

3

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.

Future Oncol. 2013 Jul;9(7):991-1003. doi: 10.2217/fon.13.56.

4

Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.

J Thorac Oncol. 2014 Oct;9(10):e78-9. doi: 10.1097/JTO.0000000000000328.

5

Comparison of the time-to-response between radiotherapy and epidermal growth factor receptor--tyrosine kinase inhibitors for advanced non-small cell lung cancer with EGFR mutation.

Anticancer Res. 2013 Aug;33(8):3279-84.

6

Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.

Clin Cancer Res. 2006 Jul 15;12(14 Pt 2):4416s-4420s. doi: 10.1158/1078-0432.CCR-06-0555.

7

Clinical significance of heterogeneity in response to retreatment with epidermal growth factor receptor tyrosine kinase inhibitors in patients with lung cancer acquiring secondary resistance to the drug.

Clin Lung Cancer. 2014 Mar;15(2):145-51. doi: 10.1016/j.cllc.2013.11.008. Epub 2013 Nov 14.

8

Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials.

Med Sci Monit. 2014 Dec 15;20:2666-76. doi: 10.12659/MSM.892476.

9

First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?

Curr Opin Oncol. 2011 Mar;23(2):131-2. doi: 10.1097/CCO.0b013e328341ee26.

10

Targeting EGFR mutation in non-small-cell lung cancer: challenges and future perspectives.

Future Oncol. 2017 Feb;13(3):201-204. doi: 10.2217/fon-2016-0325. Epub 2016 Sep 14.